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ABSTRACT: Despite being a critical molecule in the brain, mass
spectrometry imaging (MSI) of cholesterol has been under-
reported compared to other lipids due to the difficulty in ionizing
the sterol molecule. In the present work, we have employed an on-
tissue enzyme-assisted derivatization strategy to improve detection
of cholesterol in brain tissue sections. We report distribution and
levels of cholesterol across specific structures of the mouse brain, in
a model of Niemann-Pick type C1 disease, and during brain
development. MSI revealed that in the adult mouse, cholesterol is
the highest in the pons and medulla and how its distribution
changes during development. Cholesterol was significantly reduced
in the corpus callosum and other brain regions in the Npc1 null
mouse, confirming hypomyelination at the molecular level. Our
study demonstrates the potential of MSI to the study of sterols in neuroscience.
Cholesterol is the most abundant individual molecularspecies in plasma membranes of animals, accounting for
approximately 20−25% of the lipid molecules in the plasma
membrane of most cells,1 with only a small proportion of
cellular cholesterol embedded in organelles. Within mem-
branes, cholesterol influences bilayer fluidity and permeability
and lipid and protein sorting in membrane trafficking.2 In the
brain, cholesterol makes up about 15% of the dry weight of
white matter (WM) and is a major component of myelin
sheaths.3 However, little is known about how sterol
concentrations vary in different anatomical locations or at
sites of focal pathology.4 Cholesterol is metabolized to
oxysterols, steroid hormones, and bile acids. These metabolic
pathways are at least partially operative in the brain, and their
metabolic products and intermediates serve as biologically
active signaling molecules.5 In light of this, it is not surprising
that impairment in sterol homeostasis and signaling is
implicated in a number of human disorders including
neurodegenerative and neurodevelopmental conditions.6,7
Dysregulation of cholesterol homeostasis has been implicated
in Alzheimer’s disease8 and multiple sclerosis,9 while inborn
errors of cholesterol biosynthesis, metabolism, and transport
can result in neurological disorders,10 such as Smith−Lemli−
Opitz syndrome (SLOS, 7-dehydrocholesterol reductase
deficiency) and Niemann-Pick disease types C1 and C2
(NPC1 and NPC2, respectively).
Traditionally, cholesterol analysis in tissue begins with
homogenization followed by lipid extraction, leading to loss of
spatial information. To better understand sterol biochemical
and physiological roles, there is a need to match molecular
abundance with the exact location. To this end, brain
dissection can be coupled to gas chromatography (GC)
mass spectrometry (MS) or to liquid chromatography (LC)
MS.8,11,12 An alternative method to map sterol concentrations
in the brain is by exploiting mass spectrometry imaging (MSI),
for example, time-of-flight (ToF) secondary-ion MS (SIMS)
MSI, where cholesterol has been detected with high intensities,
even at subcellular resolutions. However, a drawback with this
approach is that ToF-SIMS is a surface-sensitive technique,
and cholesterol has been shown to migrate to and crystallize on
the surface, covering up all colocalizing species in the tissue.
Matrix-assisted laser desorption/ionization (MALDI)-MSI has
been employed to detect and identify multiple molecular
species and simultaneously map their distribution in tissue
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sections.13,14 It can generate pixelated MS data at near-cellular
resolution, providing spatial mapping of protein, peptide, and
lipid molecules according to X−Y position on a tissue
section.15,16 MALDI-MSI has been used to image lipids in
the brain;17 however, cholesterol and other sterols tend to be
poorly ionized by conventional MALDI and are discriminated
against when compared to lipid classes that are easily ionized.
Cholesterol has been detected in MALDI-MSI studies,18 but to
enhance ionization, other desorption methods have been
employed, including nanostructure-initiator MS,19 sputtered
silver MALDI,20 and silver nanoparticle MALDI.21 Silver ions
coordinate with carbon−carbon double bonds, providing
cationic adducts of sterols in the MALDI matrix. Recently,
“MALDI-2”-MSI has been developed, where a postdesorption
second-tuneable laser enhances the ionization of neutral lipid
species including cholesterol, allowing improved visualization
in tissue sections.22 Alternatively, derivatization strategies can
be utilized to enhance sterol ionization. For in-solution studies,
we and others have exploited enzyme-assisted derivatization
for sterol analysis (EADSA)23,24 where the sterol molecule is
reacted first with the cholesterol oxidase enzyme to oxidize the
3β-hydroxy group to 3-oxo and then with Girard-P (GP)
hydrazine to give a charge-tagged sterol hydrazone (Figure 1).
This strategy enhances the MS signal and provides unique
structural information upon multistage fragmentation (MSn)
which, together with the retention time and accurate mass
measurements, can provide unambiguous identification, even
of isomeric species. Of note, others have similarly exploited a
Girard-T hydrazine to derivatize and visualize by MSI steroid
molecules, already possessing an oxo function.25,26
We have adapted EADSA to MSI in order to image
cholesterol in the developing and adult mouse brain and in a
mouse model of Niemann-Pick C1 disease (Npc1 null) at 30−
50 μm pixel size. We demonstrate the use of isotope-labeled
standards to determine the absolute quantity of cholesterol in
different anatomical regions of the mouse brain. A quantitative
MSI of the adult wild-type (WT) mouse in sagittal sections
was determined by identifying the pons and medulla of the
brain stem as the regions with the highest cholesterol level.
The WT mouse was compared to the Npc1 null mouse
showing a significant reduction of cholesterol in the corpus
callosum. In the WT mouse brain at birth, cholesterol is the
highest in the pontine hind brain that will develop into the
cholesterol-rich pons region in the adult mouse. The
derivatization-based method has potential to be expanded to
low abundance sterols, while simultaneously detecting other
nonderivatized lipid classes.
■ MATERIALS AND METHODS
The aim of the study was to develop an MSI method suitable
to map the distribution and to determine the concentration of
cholesterol in different anatomical regions of mouse brain.
Chemicals and Reagents. HPLC-grade methanol, prop-
an-2-ol, acetonitrile, ethanol, xylene, and industrial methylated
spirit were from Fisher Scientific (Loughborough, UK). Glacial
acet ic acid was from VWR (Lutterworth, UK).
[25,26,26,26,27,27,27-2H7]Cholesterol was from Avanti Polar
Lipids (Alabaster, AL). Cholesterol oxidase from Streptomyces
sp., and potassium dihydrogen phosphate, Luxol Fast Blue
(LFB), Cresyl Violet (CV), DPX mountant, paraformaldehyde
(PFA), lithium carbonate, and α-cyano-4-hydroxycinnamic
acid (CHCA) were from Merck (Dorset, UK). GP-hydrazine
was from TCI (Zwijndrecht, Belgium).
Experimental Models. In the present study, adult WT and
Npc1−/− mice and the phenotypically normal newborn
Dhcr7T93M/+ mouse were employed. Details can be found in
Supporting Information Methods.
Tissue Sectioning. Brain tissue, mounted on and only
partially embedded in the optimal cutting temperature (OCT)
compound, was cryosectioned using a Leica Cryostat CM1900
(Leica Microsystems, Milton Keynes, UK) at a chamber
temperature of −18 °C into 10 μm-thick sections which were
thaw-mounted onto optical microscope slides for histology or
onto indium tin oxide (ITO)-coated glass slides for MSI and
stored at −80 °C until use. ITO-coated glass slides (8−12
Ohm/Sq) were from Diamond Coatings (Halesowen, UK).
Three sections were mounted on each glass slide, and each
section was separated by 100 μm from the adjacent section,
that is, the nine sections in between were placed on other
consecutive slides.
Histology. Tissue sections adjacent to sections analyzed by
MSI were thawed, fixed in PFA to preserve anatomy, and
Figure 1.MSI of cholesterol in WT mouse brain exploiting on-tissue EADSA. (A) EADSA process occurs in two steps where the 3β-hydroxy-5-ene
group is first converted to a 3-oxo-4-ene by the enzyme cholesterol oxidase and then charge-tagged with the GP hydrazine. (B) Typical mass
spectrum generated in an EADSA-MALDI-MSI experiment for a single pixel. The spectrum, in the m/z range 500−550, is dominated by the signals
of derivatized endogenous cholesterol at m/z 518.4 and sprayed-on standard [2H7]cholesterol at m/z 525.4. In each pixel, the peak at 518.4 is
normalized to the peak at 525.4, and an MS image of the distribution of cholesterol across the mouse brain tissue section is created as shown in
(C). MSI data were acquired on a vacuum-MALDI-TOF MS at a pixel size of 50 μm and visualized with an isolation window width of 0.5 m/z. See
Supporting Information, Table S1 for instruments used in each figure.
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subjected to LFB histology with cresyl violet as the
counterstain27 (Supporting Information Methods). Histolog-
ical data were analyzed by QuPath28 and ImageJ (NIH)
following whole-section digitization at 400× magnification
using a Zeiss AxioScanner.
Region of Interest (ROI) Analysis and Quantitative
Morphometry. Quantitative analysis of histological data was
carried out as follows. To assess fiber myelination, the caudate-
putamen ROI was outlined on the digitized images with
QuPath. Images of defined ROI were cropped and converted
into an 8-bit format with ImageJ to mark and measure specific
areas. The threshold was adjusted to exclude cell nuclei and
automatically outline WM areas exclusively, and the total WM
area was measured per section. These data were used to
calculate the percentage of myelinated fibers in the selected
ROI. Cerebellar area and length of the Purkinje cell layer were
also defined with QuPath, and Purkinje cells were manually
counted to determine cell linear density.
Stereology. Stereological methods were employed to
identify ROI within mouse brain sagittal tissue sections. The
defined ROI was employed to analyze both the MSI and the
histology data. For determination of ROI, we referred to the
Allen Mouse Brain Atlas (AMBA, Allen Institute for Brain
Science) (sagittal sections, P56, https://atlas.brain-map.org/
atlas?atlas=2).29 Details can be found in Supporting
Information Methods.
Deposition of the Standard and On-Tissue EADSA.
This was performed as described in ref 30 with minor
modifications. Mouse brain sections mounted on an ITO-
coated glass slide were transferred from a −80 °C freezer to a
vacuum desiccator. After 15 min dessication, [2H7]cholesterol
(200 ng/μL in ethanol) was sprayed from a SunCollect sprayer
(SunChrom, Friedrichsdorf, Germany, supplied by KR
Analytical Ltd, Cheshire, UK) at a flow rate of 20 μL/min at
a linear velocity of 900 mm/min with a 2 mm line distance and
height of 30 mm from the section in a series of 18 layers. The
resulting density of the deuterated standard was 40 ng/mm2
(see below). The sprayer was thoroughly flushed with about 2
mL of methanol after which cholesterol oxidase (0.264 units/
mL in 100 μM KH2PO4 pH 7) was sprayed for 18 layers. The
first layer was applied at 10 μL/min, the second was applied at
15 μL/min, and then all the subsequent layers were applied at
20 μL/min to give an enzyme density of 0.05 munits/mm2.
Thereafter, the enzyme-coated slide was placed on a PTFE bed
in a glass jar (11 cm × 11 cm × 7.5 cm) above 30 mL of warm
water (37 °C) and then incubated at 37 °C for 1 h. The slide
was removed, and the tissue was dried in a vacuum desiccator
for 15 min. GP (5 mg/mL in 70% methanol, 5% acetic acid)
was sprayed on the dried slide with the same spray parameters
as used for spraying of cholesterol oxidase. The resulting GP
density was 1.00 μg/mm2. The slide was then placed in the
custom-made humidity chamber as mentioned above contain-
ing 10 mL of prewarmed (37 °C) 50% methanol and 5% acetic
acid and incubated at 37 °C for 1 h. The slide was removed
and dried in a vacuum desiccator and then stored in a cold
room (4 °C) until MSI analyses. Desorption electrospray
ionization (DESI)-MSI experiments were performed without
any further pretreatment. For MALDI-MSI, on the next day,
the desiccator was allowed to reach room temperature, and
then, the slide was removed and sprayed with the CHCA
matrix. CHCA was sprayed from an HTX TM-sprayer (HTX
Technologies, NC, USA) at 5 mg/mL in water/propan-2-ol/
acetonitrile (3:4:3, v/v/v) at a flow rate of 80 μL/min and a
linear velocity of 1200 mm/min, with 2 mm line distance and a
criss-cross deposition method which alternates vertical and
horizontal passes, for a total of 8, with an offset of 1 mm,
resulting in a matrix density of 1.33 μg/mm2. The sprayer
nozzle was heated at 70 °C to enhance the solvent evaporation
rate.
Mass Spectrometry Imaging. Following EADSA treat-
ment, tissues sections were analyzed using different mass
spectrometers. Optimized instrumental parameters are de-
scribed below.
Vacuum MALDI-TOF-MSI. Experiments were carried out
on an ultrafleXtreme MALDI TOF/TOF mass spectrometer
(Bruker Daltonics, Bremen, Germany) equipped with a
Smartbeam Nd:YAG laser emitting at 355 nm (2 kHz) and
operated in the reflectron mode and positive polarity. Each
mass spectrum was automatically acquired using the
autoexecute method in FlexControl (Bruker) software in the
m/z range of 400−1000. The pixel size was set at 50 μm using
flexImaging 4.1 software (Bruker), setting laser focus to
“small”. The laser spot size was about 50 μm, according to
factory specifications and as verified by visual inspection with
the instrument camera. Each raster was sampled with 200 shots
in five steps for a total of 1000 shots per raster. The total
acquisition time was typically about 11.5 h for a total of
∼27,000 positions. The MALDI instrument was calibrated
using a mixture of phosphatidylcholine and lysophosphatidyl-
choline (Avanti Polar Lipids). After measurement, imaging
spectra were recalibrated using the batch process in
flexAnalysis. On-tissue, mass accuracy was typically within
∼100 ppm of the theoretical mass. Data were analyzed and
visualized using flexImaging 3.0 (Bruker) and SCiLS Lab
2014b (SCiLS, Bremen, Germany) without any processing
step. Data were visualized using normalization to [2H7]-
cholesterol at m/z 525.5. Mass selection windows for ions of
interests were chosen with a width of ±0.25 Da in flexImaging
3.0 and of ±0.125% in SCiLS Lab 2014b. A mass resolution of
20,000 (fwhm) was typically achieved in a single pixel. An
optical image of each tissue section was acquired prior to the
MS acquisition by means of a flatbed scanner.
AP-MALDI-MSI. MSI was carried out in the positive-ion
mode with an Orbitrap Elite hybrid linear ion trap (LIT)-
Orbitrap mass spectrometer (ThermoFisher Scientific)
coupled with an AP-MALDI UHR source (MassTech,
Maryland USA, supplied by KR Analytical Ltd) equipped
with a Nd:YAG laser emitting at 355 nm. Full scan (MS1)
imaging analysis was performed with m/z measurement in the
Orbitrap over the m/z range of 400−1200 at 60,000 resolution
(fwhm at m/z 400), MALDI laser energy was set at 45% of the
maximum, and frequency was 1.5 kHz. Data were acquired in
the constant speed raster (CSR) mode at a scan speed of 2.8
mm/min and a pixel size of 30 μm. A lock mass for
[2H7]cholesterol at m/z 525.4544 was employed. The
acquisition of one mouse brain tissue section was achieved
in about 15 h. In MS3 experiments, the MALDI laser energy
was set at 14% and frequency was 1.5 kHz. Data were acquired
in the CSR mode at a scan speed of 3 mm/min and a pixel size
of 40 μm. In the LIT, precursor ions were isolated and
fragmented with an isolation width of 2 and an arbitrary
collision-induced dissociation (CID) energy of 35%. The most
intense fragment ion produced in MS2 was selected with an
isolation width of 2 and fragmented with a CID energy of 40%
to produce an MS3 spectrum. MS3 spectra of cholesterol and
[2H7]cholesterol were acquired in each pixel. The MS
3
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transitions for cholesterol and [2H7]cholesterol were 518.4 →
439.4→ and 525.4 → 446.4 →, respectively.
Data were analyzed and visualized using ImageQuest
(ThermoFisher Scientific). Alternatively, after exporting the
file into an imzml format, data were analyzed by SCiLS Lab
MVS 2014c (SCiLS, Bremen, Germany) without any
processing step. MS1 data were normalized to [2H7]cholesterol
at m/z 525.454. Ions of interests were extracted with a width of
7 mDa and 0.3 Da for MS1 and MS3 scans, respectively.
Vacuum-MALDI-Q-IM-TOF MSI. Experiments were car-
ried out on two Synapt G2-Si instruments (Waters, Wilmslow,
UK) exploiting Waters HDI 1.4 software for acquisition and
image visualization. Images were generated from spectra
acquired in the positive-ion mode in the m/z range 400−
1000. The laser frequency was 1 kHz, and power was kept at
100 arbitrary units. The scan time was 0.5 s, and the pixel size
was 50 μm. IMS cell wave velocity was from 1000 to 300 m/s,
and transfer wave velocity was 281 m/s. In all experiments, the
cholesterol signal was measured to better than 5 ppm mass
accuracy.
DESI-Q-IM-TOF MSI. Experiments were carried out on a
Synapt G2-Si. Spectra were acquired in the positive ion mode
in the m/z range 100−1200, with a needle voltage of 4.5 kV.
The DESI solvent flow rate was 1.25 μL/min. The scan time
was 0.25 s, and the pixel size was 25 μm. IMS cell wave velocity
was from 1000 to 300 m/s, and transfer wave velocity was 281
m/s. In all experiments, the cholesterol signal was measured
with a mass accuracy better than 8 ppm.
Quantification. Known amounts of [2H7]cholesterol were
sprayed on tissue prior to the EADSA process. This procedure
corrects for variation in the matrix effect and MS response. The
linearity of the on-tissue response of sprayed-on [2H7]-
cholesterol verses endogenous cholesterol was determined by
spraying eight consecutive tissue sections with [2H7]-
cholesterol at varying densities (endogenous cholesterol areal
density is assumed to be constant for a given ROI across the
consecutive slices). Quantification was made from [M]+ ion
signal intensities, averaged in each brain region. Brain regions
of interest were defined according to AMBA. The areal density
of cholesterol in defined regions of interest was calculated by
correlating signal intensity to that of known density of
[2H7]cholesterol sprayed on tissue. All quantitative measure-
ments were analyzed employing SCiLS Lab MVS 2019c
(SCilS, Bremen, Germany).
Statistics. To determine statistical difference in cholesterol
areal density between defined regions of interest in five adult
WT mice, two-way ANOVA was performed with cholesterol
areal density as the dependent variable and the mouse and
brain region as factors. The interaction between the mouse and
brain region was used as error variance. The residuals
representing the interaction deviations were approximately
normally distributed. Tukey’s multiple comparisons test was
used to identify significant differences between brain regions.
Statistical analysis was applied for the assessment of myelinated
fiber density and specific cell counts, in defined brain regions
of WT and Npc1−/− mouse brain. Five WT and three Npc1−/−
brains were employed, analyzing three or more sections for
each mouse.
To determine statistical differences in cholesterol areal
density in defined regions of interest between WT and
Npc1−/− mouse brain, a Shapiro−Wilk test for normality was
performed, followed by an unpaired t-test for significance. The
analyses were performed using GraphPad Prism 8.2.1 software
(GraphPad Software, Inc, CA, USA). A P-value of less than
0.05 was considered statistically significant. P < 0.05, *; P <
0.01, **; and P < 0.001, ***. All whiskers on bar graphs
represent 1 standard deviation. Note that one of the five
control mice was not considered in the calculation of the
average cholesterol areal density for the caudate-putamen as it
was not sectioned on an equivalent anatomical plane.
■ RESULTS AND DISCUSSION
In MALDI-MS and electrospray ionization (ESI)-MS,
cholesterol is poorly ionized and is often detected as the
Figure 2. MS3 fragmentation patterns of (A) tissue-endogenous cholesterol and (B) sprayed-on [2H7]cholesterol, in a single pixel obtained in the
LIT of an AP-MALDI-Orbitrap Elite after on-tissue EADSA of a mouse brain tissue section and of (C) cholesterol and (D) [2H7]cholesterol
reference standards obtained in the LIT of an ESI-Orbitrap Elite following in-solution EADSA. The MS3 spectra were obtained for the transitions
[M]+ → [M − Py]+→. (E,F) MSI of the distribution of the MS3 fragment ion at m/z 163 from (E) cholesterol and (F) [2H7]cholesterol in a
sagittal brain section of WT adult mouse.
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ammonium adduct [M + NH4]
+ at m/z 404.39 or as the
dehydrated protonated molecule [M + H−H2O]+ at m/z
369.35.31 In this study, to enhance ionization of sterols, we
exploit the EADSA method, previously used for in-solution
analysis of sterols. Once the sterol analyte is specifically and
effectively charge-tagged by EADSA (Figure 1A), it is readily
analyzed by MSI, thereby allowing its detection and
identification (e.g., by MS3) and the mapping of its
distribution. The advantage of this methodology is fourfold
in that it (i) greatly increases sensitivity, (ii) allows for absolute
quantification, (iii) enhances structural information, and,
equally importantly, (iv) increases analytical specificity. Here,
we report how EADSA has been adapted to work on brain
tissue sections for MSI studies.
Quantitative MSI of Sterols in WT Mouse Brain. Initial
studies were performed using sagittal mouse brain sections
with a MALDI-TOF instrument. GP-tagged cholesterol gives
an intense [M]+ signal, as does sprayed-on [2H7]cholesterol,
and dominates the resulting mass spectrum (Figure 1B). An
MS image of cholesterol distribution, normalized in each pixel
to [2H7]cholesterol sprayed-on standard, is shown in Figure
1C.
To confirm the identity of the signals assigned to
cholesterol, we separately carried out MS3 ([M]+ → [M −
Py]+→, where Py corresponds to the pyridine component of
the GP-tag, see Supporting Information, Figure S1) analysis of
the peaks at m/z 518.41 (cholesterol) and m/z 525.45
([2H7]cholesterol) using AP-MALDI on an Orbitrap Elite, see
Figure 2. In Supporting Information, Figure S1, structures of
the major fragment ions observed in Figure 2 are described.
The fragment ion at m/z 163 (*b3-28) is formed by cleavage of
the A/B ring and is devoid of the CD rings and the side chain.
It is present in MS3 spectra of both cholesterol (Figure 2C)
and [2H7]cholesterol (Figure 2D) authentic standards and can
thus be exploited in a multiple reaction monitoring (MRM)-
like experiment to confirm the location of tissue-endogenous
cholesterol and sprayed-on [2H7]cholesterol in each pixel
(Figure 2A,B, respectively). Figure 2E shows that the MRM
transition 518.4 → 439.4 → 163 is essentially absent off tissue,
while most notably enriched in the midbrain, pons, medulla,
and WM tracts of the cerebellum. Conversely, Figure 2F shows
that the MRM transition 525.5 → 446.4 → 163 is saturated off
tissue, while being quite evenly distributed on tissue. This
transition does show some variation on tissue due to matrix
effects. For MS3 data, the current software does not allow
automated normalization of cholesterol signals to the internal
standard.
Using MS1, areal densities were determined against a known
density of the sprayed-on internal standard in WT mouse brain
sections, for selected brain structures (Figure 3A). The
linearity of the on-tissue response of endogenous cholesterol
versus the sprayed-on deuterated standard was determined by
spraying eight consecutive tissue sections with [2H7]-
cholesterol at varying known densities (Supporting Informa-
tion, Figure S2A). Examples of calibration curves obtained on
whole-brain sections and considering the cerebellum as an ROI
Figure 3. Quantitation of cholesterol in WT adult mouse brain via MSI. (A) LFB/CV staining for myelin of a sagittal mouse brain section adjacent
to a section undergoing MSI. Major anatomical structures were identified by comparison with the AMBA29 and are outlined with dashed lines:
olfactory traits, OLF; cortex, CTX; corpus callosum, CC; caudate-putamen, CP; thalamus, TH; hypothalamus, HY; hippocampus, HP; midbrain,
MB; pons, P; medulla, MY; cerebellum, CBX; and cerebellar white matter, CBX WM. (B) Areal density (ng/mm2) of cholesterol in brain regions
from five WT mice, averaged over different slices (see the Statistics section). Values for individual mice are given by separate histogram bars. The
three dots within each bar correspond to region averages for each brain slice employed. The height of each bar represents the mean of the region
average for each mouse across the three slices. The error bars indicate the SD of all the sections per mouse. Data were acquired on a vacuum-
MALDI-TOF MS instrument.
Analytical Chemistry pubs.acs.org/ac Article
https://dx.doi.org/10.1021/acs.analchem.0c05399
Anal. Chem. XXXX, XXX, XXX−XXX
E
are shown in Supporting Information, Figure S2B,C,
respectively. R2 for the whole brain was determined to be
0.94, and for the cerebellum, it was determined to be 0.97. Our
quantitative data reported in Figure 3B and in Supporting
Information, Table S2 (ng/mm2, mean of five biological
replicates ± standard deviation) indicate that cholesterol
abundance is the highest in the pons (681.6 ± 123.9 ng/mm2)
and cerebellar white matter (652.0 ± 119.8 ng/mm2) and the
lowest in the olfactory traits, cortex, and hippocampus (348.5
± 52.4, 327.8 ± 32.5, and 326.3 ± 31.6 ng/mm2, respectively).
Note that cholesterol was quantified via MSI in the whole
cerebellum and separately in its WM tracts, whereas
cholesterol content in cerebellar grey matter (GM) is
estimated from the difference of the total and WM. In
previous reports,11 cholesterol synthesis and concentration
were found to be higher in regions of the central nervous
system (CNS) containing heavily myelinated fiber tracts such
as the brain stem (medulla and pons) and the midbrain.
In an early report,8 it was shown that the concentration of
cholesterol in the pons is ∼2.5 times more than in the cortex,
which is also in agreement with our data showing a ratio of 2.1.
In earlier MSI studies, cholesterol was visualized in mouse
brain in coronal or horizontal sections.18,20,32 Sagittal MS
images have the advantage that the brain stem can be easily
differentiated into the midbrain, pons, and medulla regions
(Figures 2E and 3A). These brain stem structures show high
cholesterol content (Figure 3 and Supporting Information,
Table S2), in agreement with previous GC−MS and LC−MS
studies.8,11
Interestingly, the distribution of gene transcripts of late-stage
cholesterol biosynthetic enzymes matches regions of high
cholesterol abundance, that is, midbrain, medulla, and pons
regions. Please see mRNA expression data of Dhcr24, entrez
ID (EID) 74754; Dhcr7, EID 13360; and Sc5d, EID 235293,
provided by the AMBA.29 Of note, the abundance of
cholesterol in the corpus callosum and in the fiber tracts of
the caudate-putamen mirrors the distribution of transcripts
unique to myelinating oligodendrocytes. See Mbp, EID 17196;
Plp1, EID 18823; and Cnp, EID 12799 provided by the
AMBA.29
When MS1 data obtained by AP-MALDI are visualized in a
peripheral sagittal section taken at a plane about 3 mm from
the midline, the distribution of GP-derivatized cholesterol at
m/z 518.4103 is clearly enhanced in specific regions of the
brain (Figure 4A). These are either WM tracts such as the
corpus callosum and cerebellum or brain regions (deep GM
structures) containing myelinated fibers, such as the pons,
medulla of the brain stem, and caudate-putamen of the
diencephalon. In Figure 4, the selected sagittal plane does not
include the midbrain but shows hippocampal features.
Notably, using our method for on-tissue cholesterol
derivatization and in contrast to ToF-SIMS, other lipids can
be mapped simultaneously, particularly when experiments are
carried out with API (i.e., AP-MALDIOrbitrap and DESI
Q-TOF). To show the potential of our approach, we report the
MS image of PC 32:0 at m/z 734.5702 (about 1 ppm deviation
from the theoretical m/z), normalized to [2H7]cholesterol
sprayed-on standard (Figure 4B), but many other peaks could
be similarly imaged. Note that the peak at m/z 734.5702 could
also be assigned to PE 35:0. However, phospholipids
containing fatty acids with an odd number of carbon atoms
are minor species in animals.
Interestingly, in Figure 4A, a continuous gradient of
cholesterol concentration is observed going out from the
corpus callosum, where cholesterol is at an areal density of
about 520 ng/mm2, decreasing on moving through the
overlying layers of the neocortex. The continuous cholesterol
gradient is mirrored by the distribution of PC 32:0 in the same
brain regions (Figure 4B). Within the cerebellum, a decreasing
concentration of cholesterol is observed going from the WM of
the cerebellum (CBX WM, 652.0 ± 119.8 ng/mm2) to the
granule cell layer and molecular layer of the GM (Figure 4D
Figure 4. AP-MALDI-MSI of cholesterol in sagittal sections of WT adult mouse brain after on-tissue EADSA. The data were obtained on an
Orbitrap instrument. (A) MSI of cholesterol. (B) MSI of PC 32:0. (C) Typical AP-MALDI-Orbitrap MS spectrum averaged over the entire MSI
data set showing signals of sterol and other brain lipids that can be detected simultaneously. (D) Anatomical layering of the cerebellum (CBX,
yellow). Image from AMBA: Adult Mouse, P56, Sagittal, Image 7 of 21 id = 100883846.29 In (A, B), the isolation window width was 7 mmu and
the pixel size was 30 μm. Images normalized against sprayed-on [2H7]cholesterol.
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shows reference anatomy). Note that cholesterol density in
cerebellar GM can be estimated (CBXCBX WM = CBX
GM) to be about 260 ng/mm2. Here, the cholesterol smooth
gradient contrasts with the step gradient shown by PC 32:0
(Figure 4B) which is deficient in the granule cell layer of the
cerebellum but more evident in the molecular layer. Further
description of MSI of cholesterol in cortical layers and
hippocampus can be found in Supporting Information, Figure
S3.
The EADSA-MALDI-MSI quantitative assessment of
cholesterol areal density in defined brain regions of the WT
mouse can be compared with measurements previously
obtained with a similar but different experimental approach
exploiting low-spatial-resolution (400 μm pixel size) liquid
extraction for surface analysis (LESA), that is, EADSA-LESA-
LC-MS.30 Supporting Information, Table S2 reports the values
obtained and their standard deviations, in each defined brain
region of WT mouse, for both the present and the EADSA-
LESA-LC-MS study. The agreement was >90% for very
homogenous regions such as the cortex and thalamus, it was
about 80% for caudate-putamen, hippocampus, pons, and
cerebellar white matter, and it was >67% for heterogeneous
midbrain and medulla.
MSI of Cholesterol in the Developing Mouse. To
illustrate how our EADSA-MSI method can be used to
monitor brain cholesterol distribution during development, we
compared tissues from mice at 1 day and 10 weeks. At birth,
myelination is in its very early stage, while at 10 weeks, it is
nearly completed.33 During development, the cholesterol
content in the whole brain goes from about 4 mg/g at birth
up to about 15 mg/g in the adult at 26 weeks34 and comes
from local synthesis only.1 During the first 3 weeks of life,
when myelin sheaths are being generated, the rates of
cholesterol synthesis and accumulation in brain are high at
about 250 μg/day11 and drop rapidly beyond 3 weeks of age.34
Most strains reach sexual maturity between 6 and 8 weeks, so
postnatal week 10 can be defined as a young adult mouse.35
EADSA-MSI was employed to visualize cholesterol dis-
tribution in the mouse brain at 1 day and at 10 weeks (Figure
5). We compared MSI of cholesterol with LFB chemical stain
and CV as a counterstaining, histological stain for myelin,27 as
shown in Figure 5C (newborn) and Figure 5D (10 weeks).
Figure 5. Quantitative MSI of cholesterol in mouse brain at birth and at 10 weeks. In (A,C,E), 1 day-old newborn, and in (B,D,F), 10 week-old
adult mouse. (A,B) AMBA images depicting mouse brain sagittal sections with annotations of anatomical structures. The 1 day-old newborn is
matched with the E18.5-day embryo atlas image (A). Pallium, Pal; telencephalic vesicle, Tel; diencephalon, D; peduncular hypothalamus, PHY;
midbrain, M; pontine hindbrain, PH; pontomedullary and medullary hindbrain, PMH + MH; prepontine hindbrain, PPH. (B) Adult mouse,
abbreviations as in Figure 3. (C,D) LFB/CV staining of sagittal mouse brain sections adjacent to sections undergoing MSI. (E,F) MSI of
cholesterol after on-tissue EADSA by vacuum-MALDI-TOF MS, normalized against sprayed-on [2H7]cholesterol, at a pixel size of 50 μm. (G)
Areal density (ng/mm2) of cholesterol in brain regions from two newborn WT mice, each averaged over four slices. The mean of the region average
for individual mice is given by separate histogram bars, and region averages in each slice are represented by dots. The error bars indicate SD. Image
from AMBA: Developing Mouse, E18.5, Image 16 of 19 id = 100740373 and Adult Mouse, P56, Sagittal, Image 15 of 21 id = 100883867.29
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Figure 5E shows the MSI of cholesterol at 1 day around the
time when oligodendrocytes start to contribute to cholesterol
synthesis,36 and Figure 5F shows the distribution at 10 weeks.
As measured by quantitative EADSA-MSI, the newborn
(Figure 5G and Supporting Information, Table S3) shows the
highest cholesterol level in the pontine hindbrain (193.4 ±
28.4 ng/mm2) and in the medullary and pontomedullary
hindbrain (180.3 ± 25.6 ng/mm2) that will develop into the
cholesterol-rich pons and medulla of the adult mouse (Figure
3B).33 The lowest levels of cholesterol are detected in the
telencephalic vesicle (111.7 ± 13.9 ng/mm2) and in the
pallium (125.1 ± 15.3 ng/mm2) which will develop into the
cortex, olfactory tracts, hippocampus, and caudate-putamen.33
Similar to the newborn, these are regions with low cholesterol
in the adult (Figure 3 and Supporting Information, Table S2)
except for the caudate-putamen which contains some fiber
tracts in the adult that are not yet formed in the newborn.33
The pro-hypothalamic region (peduncular hypothalamus),
which begets the adult hypothalamus and associated fiber
tracts, shows a diffused enrichment in cholesterol in the
newborn (Figure 5A,E), while the hypothalamus in the adult
accumulates cholesterol only in surrounding fibers (Figure
5B,F). A striking difference between 1 day and 10 week
animals is the lack of a visible corpus callosum (CC) in the
newborn. In the mouse, myelination of the CC is reported to
begin at 11 days after birth37 and CC is detected by
histological methods at around 16−17 days of age.37 In
contrast to the newborn, in the 10 week adult, the CC is fully
formed.35 In particular, in the adult, the thicker regions of the
CC show enrichment in cholesterol, namely, the rostrum-genu
(frontal, 504.3 ± 57.7 ng/mm2, see Supporting Information,
Figure S4), the body (central, 546.2 ± 66.3 ng/mm2), and the
splenium (back, 500.4 ± 35.3 ng/mm2), while the thinnest
part of the CC which is the isthmus connecting the body and
the splenium is the CC structure with the lowest cholesterol
abundance (457.8 ± 51.2 ng/mm2).
Worthy of note, the nonspecific LFB myelin stain of the
newborn provides little distributional information when
compared to the MSI heat map for cholesterol (Figure 5C cf
5E). Importantly, MSI, as applied here, is specific for
cholesterol, while the exact molecular species bound by LFB
remain uncertain.38 Notably, the cholesterol distribution in the
Figure 6. Histology-matched quantitative MSI displaying cholesterol distribution and quantification in brain tissue sagittal sections of WT and
Npc1−/− mice. (A,B) MSI of cholesterol in WT (A) and in Npc1−/− (B) mouse brain tissue. The cholesterol signal was normalized to the signal of
sprayed-on [2H7]cholesterol. Data acquired using vacuum-MALDI-TOF MS at 50 μm pixel size. (C,D) LFB/CV staining of sections adjacent to
MSI. Major anatomical structures were identified by comparison with the AMBA31 and are outlined with dashed lines. Abbreviations are the same
as in Figure 3. (E) Myelinated fiber density in the CP and (F) Purkinje cell counts in the CBX of WT and of Npc1−/− mice, as assessed by
quantitative morphometry of stained sections. (G) Areal density (ng/mm2) of cholesterol in brain regions from five WT and three Npc1−/− mice.
Group averages are given by separate histogram bars. Dots within each bar correspond to the individual mouse average. (■CTRL or •KO). The
error bars indicate the SD. Data were acquired on a vacuum-MALDI-TOF MS instrument.
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newborn mouse imaged by vacuum MALDI-TOF (Figure 5E)
is consistent with the image of an adjacent brain section
produced by DESI-Q-TOF (Supporting Information, Figure
S5E), proving the robustness of the EADSA-MSI approach.
Finally, as measured by EADSA-MSI, the whole-brain areal
density of cholesterol in the newborn is about 160 ng/mm2,
while it is about 480 ng/mm2 in the adult at 10 weeks, showing
a threefold increase. Our data are in good agreement with
previous reports11 where the cholesterol content in the
newborn was determined to be about 4 mg/g at birth and to
increase to about 10 mg/g at 10 weeks, showing a 2.5-fold
increase. In summary, the present data demonstrate that
EADSA-MSI can be used effectively to monitor cholesterol
abundance in brain structures during development.
MSI of Cholesterol in the Niemann-Pick Disease Type
C1 Shows a Lack of Cholesterol in Hypomyelinated
Fibers Tracts. Niemann-Pick disease, type C is a neuro-
degenerative, lysosomal storage disorder, characterized by
accumulation of unesterified cholesterol and sphingolipids in
the endo-lysosomal system.39 The disease is caused by
mutations in the encoding region of genes either for the
lysosomal transmembrane protein, NPC1 (95% of cases), or
the cholesterol-binding soluble glycoprotein, NPC2 (∼4% of
cases).39 These two proteins work together to transport
cholesterol through the late endosomal−lysosomal membrane
into the metabolically active cholesterol pool. Patients with
NPC disease show extensive hypomyelination that manifest in
cerebral and cerebellar atrophy and WM hypoplasia.40
In the present study, we analyzed the cholesterol content
and distribution in the brain of the Npc1−/− mouse.41 In the
brain of this mouse, at the 7 week time point, cellular
dysfunction translates into loss of many large neurons. Purkinje
cells of the cerebellum are particularly sensitive to NPC
pathology and are largely lost in patients42 and in the mouse
model.43 Moreover, the brain of the Npc1−/− mouse generally
shows severe dysmyelination of fiber tracts with impairment of
oligodendrocyte maturation.36 As in patients,40 oligodendro-
cyte loss and dysmyelination may result in hypoplasia of the
corpus callosum in this mouse model.44 When NPC1/2
proteins are lacking, cholesterol and other lipids remain in the
late endosomes/lysosomes and are not transported into the
endoplasmic reticulum (ER) and, therefore, sterol homeostasis
is undermined by the lack of feedback regulatory mechanisms,
that is, free cholesterol accumulates in the late endosome/
lysosome compartment, while the rest of the cell perceives a
shortage of sterol. Recently, one MSI study has assessed lipid
changes in this Npc1−/− mouse but was limited to the
cerebellum.18
In the present study, we have exploited MSI to study the
whole brain. The chosen time point was of 10 weeks when the
phenotype is severe but not yet lethal: Npc1−/− mice die
around 12 weeks of age.45 Figure 6A,B shows the MSI heat
maps of cholesterol distribution in WT and Npc1−/− mouse
brain, respectively. These heat maps can be compared with
Figure 6C,D, showing LFB/CV staining for myelin of the
corresponding adjacent brain tissue sections. For further
comparison of MSI with histology, the density of myelinated
fibers in the caudate-putamen (Figure 6E and Supporting
Information S6A) and the number of Purkinje cells in the
cerebellum (Figure 6F and Supporting Information S6B) of
WT and Npc1−/− mouse were determined from the histological
data obtained via LFB/CV staining. Figure 6G shows
cholesterol levels in selected brain ROI, as quantified by MSI
for the Npc1−/− and WT mice. The quantitative data reported
in Figure 6G and in Supporting Information, Table S2 indicate
that in Npc1−/− brain, cholesterol is most abundant in the
cerebellar white matter, medulla, and pons (462.1 ± 58.7,
461.6 ± 111.3, and 454.2 ± 49.5 ng/mm2, respectively) and
least abundant in the cortex and hippocampus (307.4 ± 36.9
and 288.9 ± 36.5 ng/mm2, respectively).
Supporting Information, Table S2 also reports the %
difference in cholesterol areal density between the Npc1−/−
and WT animals. The regions showing the highest reduction of
cholesterol in the Npc1−/− mouse compared to the WT are the
corpus callosum (34.4%), pons (33.4%), cerebellar WM
(29.1%), and midbrain (27.8%) (p-values are indicated in
Figure 6G).
A comparison of histological and MSI data in WT and
Npc1−/− mouse brain reveals structural differences that can be
correlated with compositional changes in cholesterol distribu-
tion and abundance. The most striking difference is in the CC.
Figure 6C shows that the CC in the WT mouse is heavily
myelinated and highlighted by the LFB dye. In contrast, Figure
6D shows that the CC is apparently nonmyelinated in the
Npc1−/− brain with the LFB stain showing this structure as
mostly white. This correlates well with our MSI data where
cholesterol areal density is significantly higher in the WT as
compared to the Npc1−/− CC (Figure 6G, ***p-value <
0.001).
Other than in the CC, the significantly higher cholesterol
areal density as determined by MSI in the caudate-putamen
region and in the cerebellar WM of the WT mouse as
compared to the Npc1−/− mouse (*p-values < 0.05, Figure 6G)
also relates to known histological markers.44 This prompted us
to further analyze histological data by assessing the percentage
of myelinated fibers in the caudate-putamen (Figure 6E and
Supporting Information S6A) and the number of Purkinje cells
in the cerebellar GM (Figure 6F and Supporting Information
S6B) of these mice. In the caudate-putamen, myelinated fiber
density assessed in LFB/CV-stained sections was found to be
significantly reduced in the Npc1−/− mouse as compared to
WT (Figure 6E and Supporting Information S6A, **p-value <
0.01), agreeing with MSI measurement of cholesterol areal
density in the same brain region (Figure 6G, *p-value < 0.05).
Focusing on the cerebellum, the MSI measurements show a
significant difference when cerebellar WM is considered
(Figure 6G, *p-value < 0.05). This is in agreement with a
previous MSI study,18 similarly showing a reduced cholesterol
signal intensity, as normalized by the total ion current (TIC),
in the cerebellum of the same Npc1−/− mouse compared to
WT. Interestingly, there is significant reduction of the number
of Purkinje cells in the GM of the Npc1−/− cerebellum (Figure
6F and Supporting Information S6B, ***p-value < 0.001).
Loss of Purkinje cells is a known phenotypic marker of
Niemann-Pick type C patients42 and animal models.43 These
neuronal cells have their cell bodies residing in the cerebellar
GM, but their myelinated axons establish postsynaptic
connections with cerebellar deep nuclei in the WM.46
Therefore, a reduction in the cholesterol content of the
cerebellar WM of the Npc1−/− mouse could be explained in
part by the loss of Purkinje cell efferent and afferent
connections.
A significant reduction in the cholesterol areal density of the
hypothalamus, midbrain, and pons in the Npc1−/− mouse
compared to WT was revealed by MSI (Figure 6G, *p-value <
0.05 and ** p-value < 0.01). Histological staining shown in
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Figure 6C,D illustrates reduced LFB stain density in these
same areas of the Npc1−/− mouse, correlating with MSI heat
maps of cholesterol in Figure 6A,B, respectively.
EADSA-MSI with Multiple Ionization Modes and
Analyzers. We assessed the robustness of our EADSA-MSI
method on different mass spectrometers having different
sources (vacuum-MALDI, AP-MALDI, and DESI) and
analyzers (Q-TOF with and without ion mobility, linear
TOF, and Orbitrap). Our data are consistent as shown for the
cholesterol distribution in adult mouse in Figures 1C, 5F, 6A,
and Supporting Information S2A all generated by vacuum-
MALDI-TOF, in Supporting Information Figure S5A
generated by MALDI-Q-IM-TOF, in Supporting Information
Figure S5C generated by DESI-Q-TOF, and in Figure 4A
generated by AP-MALDI-Orbitrap. Altogether, these data
illustrate the reproducibility and robustness of our EADSA-
MSI methodology.
■ CONCLUSIONS AND PERSPECTIVE
The EADSA-MSI method presented provides a tool for the
quantitative imaging of cholesterol in mouse brain tissue
sections. On-tissue EADSA was successfully employed to
improve the analytical power of MSI toward sterols, allowing
quantitative mapping of cholesterol at pixel sizes down to 30
μm. Different MS platforms were utilized including vacuum-
MALDI-TOF, vacuum-MALDI-Q-IM-TOF, AP-MALDI-Orbi-
trap, and DESI-Q-TOF, demonstrating the robustness of the
method toward different ionization sources, analyzers, and
detectors. With atmospheric pressure ionization-MSI (AP-
MALDI-Orbitrap and DESI-Q-TOF), the method allowed
detection of other lipid classes (phospholipids) in parallel to
derivatized sterols, thereby extending the reach of the
methodology to the characterization of diverse lipid markers
simultaneously. Experiments are underway to extend the reach
of the methodology to less abundant and isomeric sterols,
including oxysterols, by integrating MS3 analyses in the
imaging workflow. MSI is a rapidly advancing technology
that can reach cellular resolution,47 thereby providing
information on changes happening both at the structural and
cellular level. Bridging MS-based lipidomics with histopathol-
ogy will allow the correlation of quantitative molecular
information with the anatomical location, opening a further
window for the entry of MSI into clinical chemistry. The
EADSA-MSI method described here for imaging of cholesterol
directly on tissue can be easily applied to a number of scientific
fields including neuroscience, pharmacology, biochemistry, and
pathology. Particularly, its application to the study of diseases
such as Alzheimer’s and multiple sclerosis has the potential to
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